Pemetrexed-based chemotherapy in patients with advanced, ALK-positive non-small cell lung cancer
AT Shaw, AM Varghese, BJ Solomon, DB Costa, S Novello, M Mino-Kenudson, MM Awad, JA Engelman, GJ Riely, V Monica, BY Yeap, GV Scagliotti
Annals of Oncology | OXFORD UNIV PRESS | Published : 2013
BACKGROUND: Anaplastic lymphoma kinase (ALK)-positive non-small-cell lung cancer (NSCLC) is highly responsive to crizotinib. To determine whether ALK-positive NSCLC is also sensitive to pemetrexed, we retrospectively evaluated progression-free survival (PFS) of ALK-positive versus ALK-negative patients who had been treated with pemetrexed-based chemotherapy for advanced NSCLC. PATIENTS AND METHODS: We identified 121 patients with advanced, ALK-positive NSCLC in the USA, Australia, and Italy. For comparison, we evaluated 266 patients with advanced, ALK-negative, epidermal growth factor receptor (EGFR)-wild-type NSCLC, including 79 with KRAS mutations and 187 with wild-type KRAS (WT/WT/WT). We..View full abstract
Awarded by National Cancer Institute
Awarded by American Cancer Society
Awarded by NATIONAL CANCER INSTITUTE
This study was supported in part by the V Foundation for Cancer Research (ATS and JAE), the Sig Adler Lung Cancer Research Fund (ATS), the National Cancer Institute P50-CA090578 (BYY), an American Cancer Society grant RSG 11-186 (DBC), and by internal funds from the MGH Cancer Center and MGH Pathology Department. ATS is the Charles W. and Jennifer C. Johnson MIT Koch Institute Clinical Investigator.ATS received consulting fees from Pfizer, Novartis, Chugai, Ariad, and Daiichi-Sankyo, and received research funding from Novartis and AstraZeneca. BJS received consulting fees from Pfizer and Lilly Oncology. DBC received consulting fees from Pfizer, Roche, and AstraZeneca. JAE received consulting fees from Novartis, Ariad, Chugai, and Sanofi-Aventis, and received research funding from Novartis and AstraZeneca. GJR received consulting fees from Abbott Molecular, Ariad, Chugai, and Foundation Medicine. GVS received consulting fees from Pfizer, Lilly Oncology, Roche, and AstraZeneca. The remaining authors (AV, SN, MMK, MA, VM, and BY) have declared no conflicts of interest.